NKTR
Nektar Therapeutics (NASDAQ: NKTR) announced that its Board of Directors granted non-qualified stock...
Article Summary
HOLD- Nektar Therapeutics (NASDAQ: NKTR) announced that its Board of Directors granted non-qualified stock options to purchase aggregate of 36,000 shares of its common stock to twenty-three newly-hired employees under Nektar's 2025 Inducement Plan.
- The stock options have an exercise price per share equal to $64.84 equal to the closing price of Nektar common stock on July 20, 2026, with the stock options having an eight-year term and will vest over four years with 1/4th of the shares vesting on the one-year anniversary of employee's grant date and 1/48th of shares monthly thereafter over the next three years subject to each employee's continued employment with Nektar on such vesting dates.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | -36.2% | 25% | 0.0 ptsDeclining (-36.2%) - NOT a growth stock |
| EPS Growth Next 5Y ? | -3.6% | 25% | 0.0 ptsNegative (-3.6%) - Declining expectations |
| Target Price Upside ? | 116.7% | 20% | 100.0 ptsMassive Upside (116.7%) - Target: $153.22 vs Current: $70.72 |
| Gross Margin % ? | 98.7% | 15% | 100.0 ptsExceptional (98.7%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -35.1% | 15% | 80.0 ptsSolid Dip (-35.1%) - Good entry zone |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About NKTR
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
- It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.
- It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F.
- Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA.
- The company was incorporated in 1990 and is headquartered in San Francisco, California.